tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Grace announces alignment with FDA on planned NDA submission for GTx-104

Grace Therapeutics (GRCE) announced details of the Company’s Type C meeting with the U.S. Food and Drug Administration. The purpose of this meeting was to obtain FDA feedback on the completed Phase 3 STRIVE-ON safety trial of GTx-104 and its planned New Drug Application submission including clinical, non-clinical, and chemistry, manufacturing, and control requirements. Based on feedback from the FDA, the Company believes that the data and regulatory packages as currently structured will be sufficient for submission of an NDA.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1